Milsted R, Sangster G, Kaye S, Calman K, Cordiner J, Soutter W, Barr W, Cunningham D, Soukop M, Kennedy J
Br J Obstet Gynaecol. 1984 Sep;91(9):927-31. doi: 10.1111/j.1471-0528.1984.tb03711.x.
Fifty-four patients with advanced ovarian cancer have been treated with combination chemotherapy using cyclophosphamide, adriamycin and cis-platinum. The toxicity of the regimen was manageable but few patients were prepared to tolerate more than 6 months of treatment. Those in complete clinical remission at that time were offered second-look laparotomy and if apparently free of disease, therapy was discontinued. Forty-seven patients could be assessed of whom 33 had had no previous therapy. Twenty-two of these were clinically free of disease after completion of chemotherapy of whom 12 had no detectable disease at second-look laparotomy. Of 14 patients who had failed previous therapy only one remains clinically free of disease. The results in the untreated patients demonstrate the primary importance of bulk reduction at initial laparotomy. The use of the regimen in patients who have failed on previous treatment or in patients with bulk disease seems to be palliative and the toxicity should be assessed in this context.
54例晚期卵巢癌患者接受了环磷酰胺、阿霉素和顺铂联合化疗。该治疗方案的毒性是可控的，但很少有患者愿意耐受超过6个月的治疗。当时处于完全临床缓解的患者接受了二次剖腹探查，如果明显无疾病，则停止治疗。47例患者可进行评估，其中33例未曾接受过治疗。这些患者中有22例在化疗完成后临床无疾病，其中12例在二次剖腹探查时未检测到疾病。在14例先前治疗失败的患者中，只有1例临床无疾病。未经治疗患者的结果表明了初次剖腹探查时减少肿瘤负荷的首要重要性。在先前治疗失败的患者或有大块肿瘤的患者中使用该方案似乎是姑息性的，应在此背景下评估其毒性。
